Last reviewed · How we verify

Methoxsalen+ECP — Competitive Intelligence Brief

Methoxsalen+ECP (Methoxsalen+ECP) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photochemotherapy agent. Area: Oncology.

marketed Photochemotherapy agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Methoxsalen+ECP (Methoxsalen+ECP) — M.D. Anderson Cancer Center. Methoxsalen combined with extracorporeal photochemotherapy (ECP) uses a photosensitizing agent activated by ultraviolet A light to induce apoptosis in circulating malignant T cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Methoxsalen+ECP TARGET Methoxsalen+ECP M.D. Anderson Cancer Center marketed Photochemotherapy agent
PUVA (8-MOP + UVA) PUVA (8-MOP + UVA) Madrilenian Group of Cutaneous Lymphomas marketed Photochemotherapy agent DNA (non-specific cross-linking)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photochemotherapy agent class)

  1. M.D. Anderson Cancer Center · 1 drug in this class
  2. Madrilenian Group of Cutaneous Lymphomas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methoxsalen+ECP — Competitive Intelligence Brief. https://druglandscape.com/ci/methoxsalen-ecp. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: